The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Key Inclusion Criteria: 1. Over 19 years of age 2. COVID-19 confirmed by a real-time RT-PCR tests 4 days prior to clinical trial enrollment 3. Patients with peripheral capillary oxygen saturation (SPO2) greater than 94% at the time of screening 4. Patients whose body temperature is measured according to the measured area without taking a fever reducer during screening: \[armpit of greater than 37.0 °C or an oral of greater than 37.2 °C; Patients with rectum greater than 37.6 °C or eardrum greater than 37.5 °C\] (Notes: Although you take a fever reducer, you can still be enrolled in after investigator's judgement whether there is fever or not.) 5. Patients with evidence of lung invasions as a result of radiation tests Exclusion Criteria: 1. Patients who need breathing device (for example, Invasive ventilation, Invasive mechanical ventilation, Extra-corporeal membrane oxygenation). 2. Patients who participated in other clinical trials related to COVID-19. 3. Patients who were administered drugs directly to COVID-19 24 hours prior to the start of the study. 4. Patients whose AST or ALT has increased by more than 5 times the normal lab value.